SEVEN FLEET CAPITAL MANAGEMENT LP
Q3 2026 Form 13-F

MOUNTAIN VIEW, DELAWARE
CIK 0002092021 · CRD 335203 · SEC-registered investment adviser
Consolidated report · includes 1 manager since Q4 2025
$511.7M Reported Value Total

SEVEN FLEET CAPITAL MANAGEMENT LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $434,581,362, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $434.6M gross asset value
Hedge Fund: $263.1M · Other: $171.4M
Source: Form ADV filed 2026-11-11
Reported value
$511.7M
Quarter over quarter
-10.4%
Holdings
85
Top-10 concentration
68.9%

Filing Structure

Reports holdings for

  • DV Trading LLC · File #028-26555 · since Q4 2025 · declared by one filing

Key People

Form ADV owners & control persons
Brian Guan-Chyun Liu
MANAGING MEMBER
Rod Seung-Hwan Lim
LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $511.7M
Positions 85
Change in reported value -15.5%
New positions 20
Exited positions 31
Position turnover 44.0%
Top-10 concentration 68.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
85 $511.7M
Q2 2026 13F
Filed Aug 15, 2026
96 $605.9M
Q1 2026 13F
Filed May 15, 2026
115 $318.3M
Q4 2025 13F
Filed Feb 26, 2026
85 $147.8M

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 CGON CG ONCOLOGY INC $133.7M 26.13%
2 TNGX TANGO THERAPEUTICS INC $55.7M 10.89%
3 RVMD REVOLUTION MEDICINES INC $54.3M 10.61%
4 PHVS PHARVARIS N V $22.2M 4.34%
5 ENTX ENTERA BIO LTD $20.0M 3.9%
6 LQDA LIQUIDIA CORPORATION $18.0M 3.53%
7 AVBP ARRIVENT BIOPHARMA INC $13.7M 2.67%
8 ELVN ENLIVEN THERAPEUTICS INC $12.0M 2.35%
9 AVTX AVALO THERAPEUTICS INC $11.8M 2.31%
10 XNCR XENCOR INC $11.1M 2.17%
11 ROIV ROIVANT SCIENCES LTD $10.6M 2.07%
12 ABVX ABIVAX SA $9.8M 1.92%
13 ASMB ASSEMBLY BIOSCIENCES INC $9.8M 1.92%
14 MANE VERADERMICS INC $9.7M 1.9%
15 PTGX PROTAGONIST THERAPEUTICS INC $6.4M 1.26%
16 DMRA DAMORA THERAPEUTICS INC $6.1M 1.2%
17 IPSC CENTURY THERAPEUTICS INC $6.1M 1.19%
18 EPRX EUPRAXIA PHARMACEUTICALS INC $5.2M 1.02%
19 AXSM AXSOME THERAPEUTICS INC. $4.4M 0.87%
20 SGMT SAGIMET BIOSCIENCES INC $4.2M 0.83%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings